Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.

Qi WX, Tang LN, He AN, Yao Y, Shen Z.

Int J Clin Oncol. 2014 Apr;19(2):403-10. doi: 10.1007/s10147-013-0561-6. Epub 2013 Apr 20.

PMID:
23605142
2.

Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.

Boquete-Castro A, Gómez-Moreno G, Calvo-Guirado JL, Aguilar-Salvatierra A, Delgado-Ruiz RA.

Clin Oral Implants Res. 2016 Mar;27(3):367-75. doi: 10.1111/clr.12556. Epub 2015 Feb 2. Review.

PMID:
25639776
3.

RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?

Van den Wyngaert T, Wouters K, Huizing MT, Vermorken JB.

Support Care Cancer. 2011 Dec;19(12):2035-40. doi: 10.1007/s00520-010-1061-0. Epub 2011 Jan 4.

PMID:
21203781
4.

Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases.

O'Halloran M, Boyd NM, Smith A.

Aust Dent J. 2014 Dec;59(4):516-9. doi: 10.1111/adj.12217. Epub 2014 Sep 27.

5.

Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies.

Qi WX, Lin F, He AN, Tang LN, Shen Z, Yao Y.

Curr Med Res Opin. 2013 Sep;29(9):1067-73. doi: 10.1185/03007995.2013.813840. Epub 2013 Jun 24. Review.

PMID:
23745518
6.

Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.

Sivolella S, Lumachi F, Stellini E, Favero L.

Anticancer Res. 2013 May;33(5):1793-7. Review.

PMID:
23645723
7.

Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.

Owosho AA, Blanchard A, Levi L, Kadempour A, Rosenberg H, Yom SK, Farooki A, Fornier M, Huryn JM, Estilo CL.

J Craniomaxillofac Surg. 2016 Mar;44(3):265-70. doi: 10.1016/j.jcms.2015.12.005. Epub 2015 Dec 20.

8.

Denosumab-related osteonecrosis of the jaw.

Diz P, López-Cedrún JL, Arenaz J, Scully C.

J Am Dent Assoc. 2012 Sep;143(9):981-4.

PMID:
22942143
9.

Review of current literature and implications of RANKL inhibitors for oral health care providers.

Epstein MS, Ephros HD, Epstein JB.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Dec;116(6):e437-42. doi: 10.1016/j.oooo.2012.01.046. Epub 2012 Aug 15. Review.

PMID:
22901640
10.

Antiresorptive drug-related osteonecrosis of the jaw.

Uyanne J, Calhoun CC, Le AD.

Dent Clin North Am. 2014 Apr;58(2):369-84. doi: 10.1016/j.cden.2013.12.006. Review.

PMID:
24655528
11.

Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.

Troeltzsch M, Woodlock T, Kriegelstein S, Steiner T, Messlinger K, Troeltzsch M.

J Can Dent Assoc. 2012;78:c85. Review.

12.

Stage 0 osteonecrosis of the jaw in a patient on denosumab.

Aghaloo TL, Dry SM, Mallya S, Tetradis S.

J Oral Maxillofac Surg. 2014 Apr;72(4):702-16. doi: 10.1016/j.joms.2013.09.008. Epub 2014 Jan 4.

13.

Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.

Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K.

J Clin Oncol. 2009 Nov 10;27(32):5356-62. doi: 10.1200/JCO.2009.21.9584. Epub 2009 Oct 5.

PMID:
19805682
14.

Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.

Turner B, Drudge-Coates L, Ali S, Pati J, Nargund V, Ali E, Cheng L, Wells P.

Urol Nurs. 2016 May-Jun;36(3):111-6, 154. Review.

PMID:
27501591
15.

Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.

Ristow O, Gerngroß C, Schwaiger M, Hohlweg-Majert B, Kehl V, Jansen H, Hahnefeld L, Koerdt S, Otto S, Pautke C.

Br J Oral Maxillofac Surg. 2014 Apr;52(4):308-13. doi: 10.1016/j.bjoms.2014.01.021. Epub 2014 Feb 26.

PMID:
24582013
16.

Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review.

de Boissieu P, Kanagaratnam L, Mahmoudi R, Morel A, Dramé M, Trenque T.

Eur J Clin Pharmacol. 2017 May;73(5):517-523. doi: 10.1007/s00228-017-2210-x. Epub 2017 Feb 10. Review.

PMID:
28188332
17.

Osteonecrosis of the jaw.

Drozdzowska B.

Endokrynol Pol. 2011 Jan-Feb;62(1):88-92. Review.

18.

Bisphosphonates in multiple myeloma: a network meta-analysis.

Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B.

Cochrane Database Syst Rev. 2012 May 16;(5):CD003188. doi: 10.1002/14651858.CD003188.pub3. Review.

PMID:
22592688
19.

Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P.

Breast Cancer Res Treat. 2010 Jul;122(1):181-8. doi: 10.1007/s10549-010-0866-3. Epub 2010 Apr 2.

PMID:
20361252
20.

Denosumab-associated osteonecrosis of the jaw--a case report.

Vyas S, Hameed S, Murugaraj V.

Dent Update. 2014 Jun;41(5):449-50.

PMID:
25073227

Supplemental Content

Support Center